Zafgen (NASDAQ:ZFGN) Earns News Sentiment Score of 0.08

News headlines about Zafgen (NASDAQ:ZFGN) have been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Zafgen earned a coverage optimism score of 0.08 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.6805949402101 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Here are some of the media headlines that may have impacted Accern’s analysis:

Several analysts recently weighed in on ZFGN shares. Zacks Investment Research upgraded shares of Zafgen from a “hold” rating to a “buy” rating and set a $5.50 target price for the company in a report on Wednesday, May 10th. ValuEngine downgraded shares of Zafgen from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Finally, Roth Capital started coverage on shares of Zafgen in a report on Thursday, April 20th. They issued a “buy” rating and a $9.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $24.33.

Zafgen (ZFGN) traded down 2.29% during mid-day trading on Tuesday, reaching $3.41. 54,757 shares of the company traded hands. The stock’s market capitalization is $93.34 million. Zafgen has a 52-week low of $2.89 and a 52-week high of $5.46. The stock has a 50-day moving average of $3.57 and a 200 day moving average of $4.12.

Zafgen (NASDAQ:ZFGN) last released its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by $0.05. Equities research analysts expect that Zafgen will post ($2.34) earnings per share for the current year.

In other Zafgen news, insider Dennis D. Kim acquired 10,000 shares of the company’s stock in a transaction dated Tuesday, July 11th. The stock was bought at an average price of $3.39 per share, with a total value of $33,900.00. Following the completion of the transaction, the insider now directly owns 21,443 shares of the company’s stock, valued at $72,691.77. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 21.20% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “Zafgen (NASDAQ:ZFGN) Earns News Sentiment Score of 0.08” was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.themarketsdaily.com/2017/08/08/zafgen-nasdaqzfgn-earns-news-sentiment-score-of-0-08.html.

About Zafgen

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Insider Buying and Selling by Quarter for Zafgen (NASDAQ:ZFGN)

Receive News & Ratings for Zafgen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply